PODCAST: A Biotech Buyout, and an Influencer Uprising
By Doug Young & Rene Vanguestaine AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will…
New Oriental Education delivers a lesson in business revival
The education giant has sealed its return to financial health with quarterly adjusted profits at a three-year high and revenues back to 92% of their level before a crackdown on…
East Buy turns Douyin setback into publicity coup
The livestreaming company found itself in the spotlight when one of its Douyin channels was blocked, and seized the chance to promote its own e-commerce platform Key Takeaways: East Buy…
Back on a profitable track, New Oriental pivots towards travel
The education and e-commerce group has rebounded into profit from a big annual loss and is aiming to break into tourism, responding to booming post-pandemic demand Key Takeaways: New Oriental…
FAST NEWS: Koolearn’s Loss Narrows as E-commerce Starts to Contribute
The latest: Koolearn Technology Holding Ltd. (1797.HK) announced on Friday its revenue dropped 36.7% to 899 million yuan ($130 million) in its fiscal year ended May 31, with its net loss narrowing…
FAST NEWS: New Oriental Education Sees New Business Revenue Coming Soon
The latest: New Oriental Education & Technology Group Inc. (EDU.US; 9901.US) reported a 48% revenue decline to $614 million and a $122 million loss during its fiscal third quarter through February,…
New Oriental Education Records Huge Loss, But Forges Ahead
China’s former leading private educator has revealed the huge costs it incurred in its first earnings report since a major industry reshuffle Key takeaways: New Oriental fell deeply into the…
Recent Articles
RELATED ARTICLES
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US -
FAST NEWS: Gracell shareholders approve merger with AstraZeneca
GRCL.US
- CHINA BULLETIN: China-India Tensions Flare with New Arrests
- CHINA BULLETIN: PMI Readings Signal Strong End to 2023
-
Cash-strapped Viva Biotech sells stake and plans spinoff
1873.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- ProfoundBio discovers the joys of having a wealthy owner
